Breaking News, Collaborations & Alliances

Quotient Sciences, CPI Form RNA Drug Development Joint Venture 

Will combine Quotient Sciences’ Translational Pharmaceutics platform with CPI’s expertise in small scale manufacture of RNA and LNP encapsulation.

Quotient Sciences, a global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. Details of the joint venture including name, branding, and operational roadmap will be announced as the collaboration progresses. The JV will combine Quotient Sciences’ Translational Pharmaceutics platform with CPI’s expertise in small scal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters